Cargando…

Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients

BACKGROUND: Kidney transplantation is the treatment of choice for patients with end-stage renal disease. OBJECTIVE: To evaluate the changes in serum soluble TNF-like weak inducer of apoptosis (sTWEAK) and fibroblast growth factor 23 (FGF-23) in hemodialysis (HD) patients and renal transplant recipie...

Descripción completa

Detalles Bibliográficos
Autores principales: Eskandari Naji, H., Ghorbanihaghjo, A., Argani, H., Raeisi, S., Safa, J., Alirezaei, A. H., Rashtchizadeh, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Avicenna Organ Transplantation Institute 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549008/
https://www.ncbi.nlm.nih.gov/pubmed/28828171
_version_ 1783255930129874944
author Eskandari Naji, H.
Ghorbanihaghjo, A.
Argani, H.
Raeisi, S.
Safa, J.
Alirezaei, A. H.
Rashtchizadeh, N.
author_facet Eskandari Naji, H.
Ghorbanihaghjo, A.
Argani, H.
Raeisi, S.
Safa, J.
Alirezaei, A. H.
Rashtchizadeh, N.
author_sort Eskandari Naji, H.
collection PubMed
description BACKGROUND: Kidney transplantation is the treatment of choice for patients with end-stage renal disease. OBJECTIVE: To evaluate the changes in serum soluble TNF-like weak inducer of apoptosis (sTWEAK) and fibroblast growth factor 23 (FGF-23) in hemodialysis (HD) patients and renal transplant recipients (RTR). METHODS: Serum samples were obtained from 30 patients on chronic HD, 30 RTRs, and 30 normal controls. Biochemical factors, sTWEAK, FGF-23, and interlukin-6 (IL-6) were measured by standard methods. RESULTS: Serum levels of sTWEAK in RTRs were significantly higher than those in the HD patients (p=0.025); RTR and HD patients had significantly lower sTWEAK levels than the controls (p=0.001 and p= 0.038, respectively). Serum levels of FGF-23 in HD patients were significantly (p=0.001) higher than those in the RTR; the level was higher in both studied groups compared to that in the controls (p=0.001 for both groups). The mean serum level of IL-6 in HD was significantly higher than that in RTR patients (p=0.013). IL-6 levels in both groups were significantly higher than those in controls (p=0.001 and p= 0.012, respectively). In HD group a negative correlation was found between FGF-23 and sTWEAK (r= 0.375, p=0.041); there were also a significant correlation between FGF-23 and IL-6 (r= 0.480, p= 0.007) and between IL-6 and sTWEAK (r= 0.409, p=0.025). CONCLUSION: We found that serum sTWEAK is decreased and FGF-23 is increased in HD and RTR groups comparing with the control group. However, further studies are needed to shed light over their direct role on atherosclerosis and cardiovascular outcomes.
format Online
Article
Text
id pubmed-5549008
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Avicenna Organ Transplantation Institute
record_format MEDLINE/PubMed
spelling pubmed-55490082017-08-21 Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients Eskandari Naji, H. Ghorbanihaghjo, A. Argani, H. Raeisi, S. Safa, J. Alirezaei, A. H. Rashtchizadeh, N. Int J Organ Transplant Med Original Article BACKGROUND: Kidney transplantation is the treatment of choice for patients with end-stage renal disease. OBJECTIVE: To evaluate the changes in serum soluble TNF-like weak inducer of apoptosis (sTWEAK) and fibroblast growth factor 23 (FGF-23) in hemodialysis (HD) patients and renal transplant recipients (RTR). METHODS: Serum samples were obtained from 30 patients on chronic HD, 30 RTRs, and 30 normal controls. Biochemical factors, sTWEAK, FGF-23, and interlukin-6 (IL-6) were measured by standard methods. RESULTS: Serum levels of sTWEAK in RTRs were significantly higher than those in the HD patients (p=0.025); RTR and HD patients had significantly lower sTWEAK levels than the controls (p=0.001 and p= 0.038, respectively). Serum levels of FGF-23 in HD patients were significantly (p=0.001) higher than those in the RTR; the level was higher in both studied groups compared to that in the controls (p=0.001 for both groups). The mean serum level of IL-6 in HD was significantly higher than that in RTR patients (p=0.013). IL-6 levels in both groups were significantly higher than those in controls (p=0.001 and p= 0.012, respectively). In HD group a negative correlation was found between FGF-23 and sTWEAK (r= 0.375, p=0.041); there were also a significant correlation between FGF-23 and IL-6 (r= 0.480, p= 0.007) and between IL-6 and sTWEAK (r= 0.409, p=0.025). CONCLUSION: We found that serum sTWEAK is decreased and FGF-23 is increased in HD and RTR groups comparing with the control group. However, further studies are needed to shed light over their direct role on atherosclerosis and cardiovascular outcomes. Avicenna Organ Transplantation Institute 2017 2017-05-01 /pmc/articles/PMC5549008/ /pubmed/28828171 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Eskandari Naji, H.
Ghorbanihaghjo, A.
Argani, H.
Raeisi, S.
Safa, J.
Alirezaei, A. H.
Rashtchizadeh, N.
Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients
title Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients
title_full Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients
title_fullStr Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients
title_full_unstemmed Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients
title_short Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients
title_sort serum stweak and fgf-23 levels in hemodialysis and renal transplant patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549008/
https://www.ncbi.nlm.nih.gov/pubmed/28828171
work_keys_str_mv AT eskandarinajih serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients
AT ghorbanihaghjoa serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients
AT arganih serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients
AT raeisis serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients
AT safaj serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients
AT alirezaeiah serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients
AT rashtchizadehn serumstweakandfgf23levelsinhemodialysisandrenaltransplantpatients